These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9443132)

  • 1. Sulfasalazine-induced fulminant hepatitis in pediatric Crohn's disease: report of two cases.
    Besnard M; Debray D; Durand P; Cézard JP; Navarro J
    J Pediatr Gastroenterol Nutr; 1998 Jan; 26(1):119-20. PubMed ID: 9443132
    [No Abstract]   [Full Text] [Related]  

  • 2. Sulfasalazine-associated encephalopathy in a patient with Crohn's disease.
    Schoonjans R; Mast A; Van den Abeele G; Dewilde D; Achten E; Van Maele V; Pauwels W
    Am J Gastroenterol; 1993 Oct; 88(10):1759-63. PubMed ID: 8105680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity after treatment with sulfasalazine.
    Haines JD
    Postgrad Med; 1986 May; 79(6):193-4, 197-8. PubMed ID: 2871549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Holoprosencephaly in a fetus with maternal medication of sulfasalazine in early gestation. A case report.
    Koyama N; Komori S; Bessho T; Koyama K; Hiraumi Y; Maeda Y
    Clin Exp Obstet Gynecol; 1996; 23(3):136-40. PubMed ID: 8894319
    [No Abstract]   [Full Text] [Related]  

  • 5. Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes.
    Mihas AA; Goldenberg DJ; Slaughter RL
    JAMA; 1978 Jun; 239(24):2590-1. PubMed ID: 26816
    [No Abstract]   [Full Text] [Related]  

  • 6. [Fulminant hepatitis in two children treated with sulfasalazine for Crohn disease].
    Besnard M; Debray D; Durand P; Fabre M; Chardot C; Cézard JP
    Arch Pediatr; 1999 Jun; 6(6):643-6. PubMed ID: 10394456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation.
    Descloux E; Argaud L; Dumortier J; Scoazec JY; Boillot O; Robert D
    Intensive Care Med; 2005 Dec; 31(12):1727-8. PubMed ID: 16283166
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulfasalazine-associated encephalopathy in a patient with Crohn's disease.
    Schoonjans R; Mast A; Van Den Abeele G; Dewilde D; Achten E; Van Maele V; Pauwels W
    Am J Gastroenterol; 1993 Sep; 88(9):1416-20. PubMed ID: 8103282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease.
    Carr-Locke DL
    Am J Gastroenterol; 1982 Sep; 77(9):614-6. PubMed ID: 6126117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
    Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab (Tysabri) for Crohn's disease.
    Med Lett Drugs Ther; 2008 May; 50(1285):34-6. PubMed ID: 18458669
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholestasis in Crohn's disease: a diagnostic challenge.
    Hilzenrat N; Lamoureux E; Sherker A; Cohen A
    Can J Gastroenterol; 1997; 11(1):35-7. PubMed ID: 9113796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic granulomatous reaction to salicylazosulfapyridine (Azulfidine) in a patient with Crohn's disease.
    Rafoth RJ
    Am J Dig Dis; 1974 May; 19(5):465-9. PubMed ID: 4151115
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-inflammatory drug treatment of Crohn's disease: a prospective evaluation of 100 consecutively treated patients.
    Goldstein F; Menduke H; Thornton JJ; Abramson J
    J Clin Gastroenterol; 1980 Mar; 2(1):77-85. PubMed ID: 6126497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfasalazine-induced fulminant hepatic failure.
    Marinos G; Riley J; Painter DM; McCaughan GW
    J Clin Gastroenterol; 1992 Mar; 14(2):132-5. PubMed ID: 1348259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result.
    Ursing B; Alm T; Bárány F; Bergelin I; Ganrot-Norlin K; Hoevels J; Huitfeldt B; Järnerot G; Krause U; Krook A; Lindström B; Nordle O; Rosén A
    Gastroenterology; 1982 Sep; 83(3):550-62. PubMed ID: 6124474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: the medical management of Crohn's disease.
    Elton E; Hanauer SB
    Aliment Pharmacol Ther; 1996 Feb; 10(1):1-22. PubMed ID: 8871440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of drug therapy for inflammatory bowel disease.
    Peppercorn MA
    Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.